Benzyl Alcohol
drugOn this page
Also known as Alcohol bencilicoAlcohol benzylicusAlcoholbenzylAlcool benzyliqueE-1519E1519FEMA NO. 2137INS NO.1519INS-1519NSC-8044UlesfiaPhenyl-methanolBenzyl alcoholSID17390015SID124891475SID144210364SID144204723SID144209645
Summary
Benzyl Alcohol (CHEMBL720) is an approved small-molecule antioxidant (ATC P03AX06); indicated across 3 conditions including parasitic infectious disease and otitis externa.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: P03AX06
- Indications: 3 conditions
- Chemistry: 108.14 Da · C7H8O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL720 |
| Name | Benzyl Alcohol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 244 |
| ChEBI | CHEBI:17987 |
| ATC | P03AX06 |
| Molecular formula | C7H8O |
| Molecular weight | 108.14 |
| InChIKey | WVDDGKGOMKODPV-UHFFFAOYSA-N |
SMILES: C1=CC=C(C=C1)CO
IUPAC name: phenylmethanol
ChEBI definition: An aromatic alcohol that consists of benzene bearing a single hydroxymethyl substituent.
Pharmacological roles (ChEBI): antioxidant.
Other ChEBI roles (chemical / environmental): solvent, metabolite, fragrance.
Also known as: Alcohol bencilico, Alcohol benzylicus, Alcohol, benzyl, Alcool benzylique, Benzyl alcohol, E-1519, E1519, FEMA NO. 2137, INS NO.1519, INS-1519, NSC-8044
Patent coverage: 195,167 distinct patent families (596,783 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Thyrotropin receptor.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| TSHR | 7.7 | Potency | 20 | nM | CHEMBL_ACT_3912121 |
| TSHR | 7.7 | Potency | 20 | nM | CHEMBL_ACT_4718838 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| parasitic infectious disease | 4 | MONDO:0005135 | EFO:0001067 |
| otitis externa | 4 | MONDO:0004795 | EFO:0009560 |
| lice infestation | 4 | MONDO:0003472 | MONDO:0003472 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).